Literature DB >> 21734300

α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies.

Youngshin Lim1, Victoria M Kehm, Edward B Lee, James H Soper, Chi Li, John Q Trojanowski, Virginia M-Y Lee.   

Abstract

Abnormally accumulated α-synuclein (α-syn) is a pathological hallmark of Lewy body-related disorders such as Parkinson's disease (PD) and dementia with Lewy body disease (DLB). However, it is not well understood whether and how abnormal accumulation of α-syn leads to cognitive impairment or dementia in PD and DLB. Furthermore, it is not known whether targeted removal of α-syn pathology can reverse cognitive decline. Here, we found that the distribution of α-syn pathology in an inducible α-syn transgenic mouse model recapitulates that in human DLB. Abnormal accumulation of α-syn in the limbic system, particularly in the hippocampus, correlated with memory impairment and led to structural synaptic deficits. Furthermore, when α-syn expression was suppressed, we observed partial clearing of pre-existing α-syn pathology and reversal of structural synaptic defects, resulting in an improvement in memory function.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734300      PMCID: PMC3144489          DOI: 10.1523/JNEUROSCI.0618-11.2011

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  50 in total

1.  Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation.

Authors:  P J Spira; D M Sharpe; G Halliday; J Cavanagh; G A Nicholson
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

2.  Comparison of modified Bielschowsky silver impregnation and anti-ubiquitin immunostaining of cortical and nigral Lewy bodies.

Authors:  S Love; J A Nicoll
Journal:  Neuropathol Appl Neurobiol       Date:  1992-12       Impact factor: 8.090

3.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

4.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.

Authors:  Philipp J Kahle; Manuela Neumann; Laurence Ozmen; Veronika Muller; Helmut Jacobsen; Will Spooren; Babette Fuss; Barbara Mallon; Wendy B Macklin; Hideo Fujiwara; Masato Hasegawa; Takeshi Iwatsubo; Hans A Kretzschmar; Christian Haass
Journal:  EMBO Rep       Date:  2002-05-24       Impact factor: 8.807

5.  alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining.

Authors:  E Gómez-Tortosa; K Newell; M C Irizarry; J L Sanders; B T Hyman
Journal:  Acta Neuropathol       Date:  2000-04       Impact factor: 17.088

6.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

7.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

8.  Control of memory formation through regulated expression of a CaMKII transgene.

Authors:  M Mayford; M E Bach; Y Y Huang; L Wang; R D Hawkins; E R Kandel
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

9.  Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Authors:  Katerina E Paleologou; Adrian W Schmid; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Ross A Fredenburg; Peter T Lansbury; Claudio O Fernandez; David Eliezer; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

10.  C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging.

Authors:  Tjakko J van Ham; Karen L Thijssen; Rainer Breitling; Robert M W Hofstra; Ronald H A Plasterk; Ellen A A Nollen
Journal:  PLoS Genet       Date:  2008-03-21       Impact factor: 5.917

View more
  55 in total

1.  Complex Effects of the ZSCAN21 Transcription Factor on Transcriptional Regulation of α-Synuclein in Primary Neuronal Cultures and in Vivo.

Authors:  Georgia Dermentzaki; Nikolaos Paschalidis; Panagiotis K Politis; Leonidas Stefanis
Journal:  J Biol Chem       Date:  2016-02-23       Impact factor: 5.157

2.  Autonomic dysfunction and plasticity in micturition reflexes in human α-synuclein mice.

Authors:  Robert W Hamill; John D Tompkins; Beatrice M Girard; Richard T Kershen; Rodney L Parsons; Margaret A Vizzard
Journal:  Dev Neurobiol       Date:  2012-06       Impact factor: 3.964

Review 3.  Cognition in movement disorders: where can we hope to be in ten years?

Authors:  David Burn; Daniel Weintraub; Bernard Ravina; Irene Litvan
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 4.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Authors:  Benjamin Dehay; Mathieu Bourdenx; Philippe Gorry; Serge Przedborski; Miquel Vila; Stephane Hunot; Andrew Singleton; C Warren Olanow; Kalpana M Merchant; Erwan Bezard; Gregory A Petsko; Wassilios G Meissner
Journal:  Lancet Neurol       Date:  2015-06-03       Impact factor: 44.182

Review 5.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

6.  Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Authors:  Lorraine V Kalia; Anthony E Lang; Lili-Naz Hazrati; Shinsuke Fujioka; Zbigniew K Wszolek; Dennis W Dickson; Owen A Ross; Vivianna M Van Deerlin; John Q Trojanowski; Howard I Hurtig; Roy N Alcalay; Karen S Marder; Lorraine N Clark; Carles Gaig; Eduardo Tolosa; Javier Ruiz-Martínez; Jose F Marti-Masso; Isidre Ferrer; Adolfo López de Munain; Samuel M Goldman; Birgitt Schüle; J William Langston; Jan O Aasly; Maria T Giordana; Vincenzo Bonifati; Andreas Puschmann; Margherita Canesi; Gianni Pezzoli; Andre Maues De Paula; Kazuko Hasegawa; Charles Duyckaerts; Alexis Brice; A Jon Stoessl; Connie Marras
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

7.  Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

Authors:  Meike Diepenbroek; Nicolas Casadei; Hakan Esmer; Takaomi C Saido; Jiro Takano; Philipp J Kahle; Ralph A Nixon; Mala V Rao; Ronald Melki; Laura Pieri; Stefan Helling; Katrin Marcus; Rejko Krueger; Eliezer Masliah; Olaf Riess; Silke Nuber
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

8.  Comparison of α-synuclein immunoreactivity in the hippocampus between the adult and aged beagle dogs.

Authors:  Ji Hyeon Ahn; Joon Ha Park; Bing Chun Yan; Jae-Chul Lee; Jung Hoon Choi; Choong Hyun Lee; Ki-Yeon Yoo; In Koo Hwang; Jin Sang Kim; Hyung-Cheul Shin; Moo-Ho Won
Journal:  Cell Mol Neurobiol       Date:  2012-09-13       Impact factor: 5.046

9.  An unexpected improvement in spatial learning and memory ability in alpha-synuclein A53T transgenic mice.

Authors:  Qi Liu; YuYu Xu; WenPing Wan; ZeGang Ma
Journal:  J Neural Transm (Vienna)       Date:  2017-12-07       Impact factor: 3.575

10.  Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.

Authors:  Franz Marxreiter; Benjamin Ettle; Verena E L May; Hakan Esmer; Christina Patrick; Christine Lund Kragh; Jochen Klucken; Beate Winner; Olaf Riess; Jürgen Winkler; Eliezer Masliah; Silke Nuber
Journal:  Neurobiol Dis       Date:  2013-07-16       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.